Oracle Investment Management Has Upped Its Holding in Epizyme (EPZM) as Market Valuation Rose; Ventas Com (VTR) Stock Price Rose While Groesbeck Investment Management Cut Stake by $779,100

June 10, 2018 - By Vivian Park

Epizyme, Inc. (NASDAQ:EPZM) Logo

Oracle Investment Management Inc increased its stake in Epizyme Inc (EPZM) by 9.21% based on its latest 2018Q1 regulatory filing with the SEC. Oracle Investment Management Inc bought 33,433 shares as the company’s stock rose 3.36% while stock markets declined. The hedge fund held 396,325 shares of the health care company at the end of 2018Q1, valued at $7.04 million, up from 362,892 at the end of the previous reported quarter. Oracle Investment Management Inc who had been investing in Epizyme Inc for a number of months, seems to be bullish on the $1.11B market cap company. The stock increased 0.31% or $0.05 during the last trading session, reaching $16. About 227,058 shares traded. Epizyme, Inc. (NASDAQ:EPZM) has risen 14.24% since June 10, 2017 and is uptrending. It has outperformed by 1.67% the S&P500. Some Historical EPZM News: 14/03/2018 – EPIZYME INC EPZM.O : WEDBUSH RAISES TARGET PRICE TO $24 FROM $21; RATING OUTPERFORM; 13/03/2018 – Epizyme Expects Existing Cash, Equivalents and Securities Sufficient to Fund Planned Ops 3Q 2019; 22/03/2018 – Epizyme at Group Dinner Hosted By Wedbush Today; 09/04/2018 – EPIZYME TAZEMETOSTAT PHASE 1 HAD FAVORABLE SAFETY FINDINGS; 23/04/2018 – Epizyme: FDA Issued Partial Clinical Hold Affecting New Enrollment; 23/04/2018 – EPIZYME INC EPZM.O – CO WILL NEED TO CONFIRM ALIGNMENT WITH FDA IN ORDER TO RESUME U.S. ENROLLMENT; 23/04/2018 – EPIZYME INC EPZM.O – EPIZYME HAS BEGUN DEVELOPING MODIFICATIONS TO ADDRESS PARTIAL CLINICAL HOLD; 12/03/2018 – Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors; 08/05/2018 – Epizyme 1Q Rev $0.00; 15/03/2018 – Epizyme Group Dinner Scheduled By Wedbush for Mar. 22

Groesbeck Investment Management Corp decreased its stake in Ventas Inc Com (VTR) by 33.82% based on its latest 2018Q1 regulatory filing with the SEC. Groesbeck Investment Management Corp sold 15,900 shares as the company’s stock rose 5.70% while stock markets declined. The institutional investor held 31,120 shares of the consumer services company at the end of 2018Q1, valued at $1.54 million, down from 47,020 at the end of the previous reported quarter. Groesbeck Investment Management Corp who had been investing in Ventas Inc Com for a number of months, seems to be less bullish one the $19.67 billion market cap company. The stock increased 0.51% or $0.28 during the last trading session, reaching $54.84. About 1.26M shares traded. Ventas, Inc. (NYSE:VTR) has declined 20.26% since June 10, 2017 and is downtrending. It has underperformed by 32.83% the S&P500. Some Historical VTR News: 30/04/2018 – Cramer also sits down with the CEOs of Allergan, Ventas and First Data Corp; 05/03/2018 HCP and Atria Senior Living Announce Agreement to Transition Management of 24 Senior Housing Communities to Atria; 27/04/2018 – VENTAS INC SEES FULL YEAR 2018 PROJECTED SAME-STORE CASH NOI GROWTH OF 0.5 PCT TO 1.5 PCT; 27/04/2018 – Ventas in Pact to Combine, Extends Leases With Brookdale Senior Living; 27/04/2018 – BROOKDALE HOLDER LAND & BUILDINGS `THRILLED’ WITH VENTAS NEWS; 27/04/2018 – Ventas 1Q Net $78.7M; 27/04/2018 – VENTAS INC – UPDATES AND IMPROVES 2018 GUIDANCE; 16/05/2018 – Ventas Declares Regular Quarterly Dividend of $0.79 Per Share; 27/04/2018 – Ventas to Pursue Sale of Brookdale Portfolio Properties Totaling Up to $30 Million in Cash Rent; 27/04/2018 – VENTAS INC SEES 2018 NORMALIZED FFO SHR $3.99

Since May 7, 2018, it had 0 insider buys, and 4 sales for $3.56 million activity. Barnes Melody C had sold 3,963 shares worth $211,505 on Monday, May 7.

More notable recent Ventas, Inc. (NYSE:VTR) news were published by: Seekingalpha.com which released: “A Landlord’s Dream – High Return With Lower Risk” on June 07, 2018, also Seekingalpha.com with their article: “Buy This Safe 5.9%-Yielding Healthcare REIT For Your DGI Portfolio” published on May 30, 2018, Businesswire.com published: “Ventas to Participate in NAREIT REITWeek 2018 Conference” on June 05, 2018. More interesting news about Ventas, Inc. (NYSE:VTR) were released by: Seekingalpha.com and their article: “If I Had To Build An Income Portfolio Today – Last Update” published on June 04, 2018 as well as Seekingalpha.com‘s news article titled: “Ventas: The Cornerstone Of My Portfolio” with publication date: May 17, 2018.

Investors sentiment decreased to 1.05 in 2018 Q1. Its down 0.15, from 1.2 in 2017Q4. It is negative, as 69 investors sold VTR shares while 189 reduced holdings. 73 funds opened positions while 199 raised stakes. 295.52 million shares or 3.42% less from 306.00 million shares in 2017Q4 were reported. Moreover, Gemmer Asset Mngmt Limited Liability Company has 0% invested in Ventas, Inc. (NYSE:VTR). Bb&T Secs Ltd Limited Liability Company holds 330,658 shares. Malaga Cove Cap Ltd Liability reported 14,616 shares or 0.39% of all its holdings. Bruni J V & has invested 4.39% in Ventas, Inc. (NYSE:VTR). Jefferies Grp Lc invested 0.03% in Ventas, Inc. (NYSE:VTR). Sfmg Llc reported 21,860 shares stake. Hsbc Holdg Public Ltd Co has invested 0.09% in Ventas, Inc. (NYSE:VTR). 7,315 are owned by Garde. Dimensional Fund Advisors Ltd Partnership holds 0.11% in Ventas, Inc. (NYSE:VTR) or 5.30 million shares. Gofen And Glossberg Ltd Liability Il reported 30,215 shares. Burt Wealth Advsrs invested in 0.02% or 629 shares. Capital Inc Ca stated it has 12,700 shares. Amica Pension Fund Board Of Trustees reported 0.46% stake. 1832 Asset Mgmt Ltd Partnership stated it has 0.04% of its portfolio in Ventas, Inc. (NYSE:VTR). Bank & Trust Of Montreal Can holds 945,088 shares.

Groesbeck Investment Management Corp, which manages about $250.00M and $137.93 million US Long portfolio, upped its stake in Tallgrass Energy Partners Lpco Com (NYSE:TEP) by 34,099 shares to 54,174 shares, valued at $2.05 million in 2018Q1, according to the filing. It also increased its holding in Cognizant Technlgy Sltns Corcl Com (NASDAQ:CTSH) by 19,650 shares in the quarter, for a total of 37,610 shares, and has risen its stake in Micron Technology Inc Com Com (NASDAQ:MU).

Among 23 analysts covering Ventas Inc. (NYSE:VTR), 2 have Buy rating, 4 Sell and 17 Hold. Therefore 9% are positive. Ventas Inc. had 67 analyst reports since July 27, 2015 according to SRatingsIntel. The stock has “Hold” rating by Jefferies on Monday, February 5. The company was downgraded on Wednesday, March 15 by Goldman Sachs. UBS maintained the shares of VTR in report on Monday, October 2 with “Neutral” rating. The stock of Ventas, Inc. (NYSE:VTR) earned “Buy” rating by Mizuho on Friday, September 4. The firm has “Sell” rating by KeyBanc Capital Markets given on Thursday, January 11. The firm has “Hold” rating by SunTrust given on Friday, October 27. On Tuesday, January 3 the stock rating was downgraded by Jefferies to “Hold”. The firm has “Overweight” rating given on Monday, October 30 by Capital One. The firm earned “Hold” rating on Friday, February 9 by Mizuho. The stock has “Neutral” rating by Mizuho on Wednesday, November 11.

Analysts await Ventas, Inc. (NYSE:VTR) to report earnings on July, 27. They expect $1.01 earnings per share, down 4.72% or $0.05 from last year’s $1.06 per share. VTR’s profit will be $362.34 million for 13.57 P/E if the $1.01 EPS becomes a reality. After $0.96 actual earnings per share reported by Ventas, Inc. for the previous quarter, Wall Street now forecasts 5.21% EPS growth.

More notable recent Epizyme, Inc. (NASDAQ:EPZM) news were published by: Streetinsider.com which released: “Epizyme (EPZM) to Present New Tazemetostat Data at ASCO and EHA” on May 17, 2018, also Streetinsider.com with their article: “Epizyme (EPZM) Phase 2 Data of Tazemetostat for Malignant Mesothelioma Met Primary Endpoint” published on June 04, 2018, Nasdaq.com published: “Report: Developing Opportunities within Silicon Motion Technology, Green Brick Partners, Alliance Resource Partners …” on June 06, 2018. More interesting news about Epizyme, Inc. (NASDAQ:EPZM) were released by: Nasdaq.com and their article: “Epizyme to Host Investor Conference Call to Discuss Interim Follicular Lymphoma Clinical Data” published on June 01, 2018 as well as Benzinga.com‘s news article titled: “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” with publication date: June 03, 2018.

Since February 5, 2018, it had 0 insider purchases, and 1 insider sale for $1.20 million activity.

Investors sentiment increased to 1.5 in 2018 Q1. Its up 0.29, from 1.21 in 2017Q4. It improved, as 13 investors sold EPZM shares while 25 reduced holdings. 22 funds opened positions while 35 raised stakes. 57.44 million shares or 0.90% more from 56.93 million shares in 2017Q4 were reported. Legal And General Plc stated it has 0% in Epizyme, Inc. (NASDAQ:EPZM). Hudson Bay Mngmt Limited Partnership owns 60,000 shares. 4,800 were reported by Great West Life Assurance Can. Bailard, a California-based fund reported 25,000 shares. Cubist Systematic Strategies Ltd has 0.03% invested in Epizyme, Inc. (NASDAQ:EPZM) for 25,531 shares. 22,829 are held by State Board Of Administration Of Florida Retirement Sys. Tekla Management Limited Liability Com accumulated 485,325 shares or 0.34% of the stock. Qs Ltd Company accumulated 82,496 shares or 0.02% of the stock. Teacher Retirement Systems Of Texas owns 10,680 shares. Federated Pa has 0% invested in Epizyme, Inc. (NASDAQ:EPZM). Primecap Management Communication Ca, a California-based fund reported 8.27 million shares. California State Teachers Retirement Sys stated it has 0% in Epizyme, Inc. (NASDAQ:EPZM). Jennison Associates Ltd Liability Corporation has invested 0.04% in Epizyme, Inc. (NASDAQ:EPZM). Rock Springs Mngmt LP accumulated 1.28 million shares or 0.97% of the stock. Barclays Public Limited Company reported 13,711 shares or 0% of all its holdings.

Among 13 analysts covering Epizyme (NASDAQ:EPZM), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Epizyme had 37 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets on Thursday, September 14 with “Buy”. The rating was maintained by Oppenheimer on Tuesday, August 1 with “Buy”. On Friday, October 27 the stock rating was maintained by SunTrust with “Buy”. The stock of Epizyme, Inc. (NASDAQ:EPZM) earned “Buy” rating by Mizuho on Thursday, August 6. The stock of Epizyme, Inc. (NASDAQ:EPZM) has “Buy” rating given on Monday, March 14 by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, April 5 by Citigroup. The firm has “Outperform” rating by Wedbush given on Tuesday, April 24. The stock of Epizyme, Inc. (NASDAQ:EPZM) earned “Outperform” rating by Leerink Swann on Wednesday, March 14. As per Wednesday, June 21, the company rating was maintained by Oppenheimer. The rating was maintained by H.C. Wainwright on Wednesday, March 14 with “Buy”.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>